Cornelie D Andela1, Han Repping-Wuts2, Nike M M L Stikkelbroeck2, Mathilde C Pronk1, Jitske Tiemensma3, Ad R Hermus2, Adrian A Kaptein4, Alberto M Pereira1, Noelle G A Kamminga5, Nienke R Biermasz1. 1. Division of EndocrinologyDepartment of Medicine, and Centre for Endocrine Tumors (CETL), Leiden University Medical Centre, Leiden, The Netherlands. 2. Division of EndocrinologyDepartment of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands. 3. Psychological ScienceUniversity of California, Merced, CA, USA. 4. Department of Medical PsychologyLeiden University Medical Centre, Leiden, The Netherlands. 5. Department of Psychiatry and Medical PsychologyMaastricht University Medical Centre, Maastricht, The Netherlands.
Abstract
CONTEXT: Patients with pituitary disease report impairments in Quality of Life (QoL) despite optimal biomedical care. Until now, the effects of a self-management intervention (SMI) addressing psychological and social issues for these patients and their partners have not been studied. OBJECTIVE: To examine the effects of a SMI i.e. Patient and Partner Education Programme for Pituitary disease (PPEP-Pituitary). DESIGN AND SUBJECTS: A multicentre randomized controlled trial included 174 patients with pituitary disease, and 63 partners were allocated to either PPEP-Pituitary or a control group. PPEP-Pituitary included eight weekly sessions (90 min). Self-efficacy, bother and needs for support, illness perceptions, coping and QoL were assessed before the intervention (T0), directly after (T1) and after six months (T2). Mood was assessed before and after each session. RESULTS: Patients in PPEP-Pituitary reported improved mood after each session (except for session 1). In partners, mood only improved after the last three sessions. Patients reported higher self-efficacy at T1 (P = 0.016) which persisted up to T2 (P = 0.033), and less bother by mood problems directly after PPEP-Pituitary (P = 0.01), but more bother after six months (P = 0.001), although this increase was not different from baseline (P = 0.346). Partners in PPEP-Pituitary reported more vitality (P = 0.008) which persisted up to T2 (P = 0.034). At T2, partners also reported less anxiety and depressive symptoms (P ≤ 0.014). CONCLUSION: This first study evaluating the effects of a SMI targeting psychosocial issues in patients with pituitary disease and their partners demonstrated promising positive results. Future research should focus on the refinement and implementation of this SMI into clinical practice.
RCT Entities:
CONTEXT: Patients with pituitary disease report impairments in Quality of Life (QoL) despite optimal biomedical care. Until now, the effects of a self-management intervention (SMI) addressing psychological and social issues for these patients and their partners have not been studied. OBJECTIVE: To examine the effects of a SMI i.e. Patient and Partner Education Programme for Pituitary disease (PPEP-Pituitary). DESIGN AND SUBJECTS: A multicentre randomized controlled trial included 174 patients with pituitary disease, and 63 partners were allocated to either PPEP-Pituitary or a control group. PPEP-Pituitary included eight weekly sessions (90 min). Self-efficacy, bother and needs for support, illness perceptions, coping and QoL were assessed before the intervention (T0), directly after (T1) and after six months (T2). Mood was assessed before and after each session. RESULTS:Patients in PPEP-Pituitary reported improved mood after each session (except for session 1). In partners, mood only improved after the last three sessions. Patients reported higher self-efficacy at T1 (P = 0.016) which persisted up to T2 (P = 0.033), and less bother by mood problems directly after PPEP-Pituitary (P = 0.01), but more bother after six months (P = 0.001), although this increase was not different from baseline (P = 0.346). Partners in PPEP-Pituitary reported more vitality (P = 0.008) which persisted up to T2 (P = 0.034). At T2, partners also reported less anxiety and depressive symptoms (P ≤ 0.014). CONCLUSION: This first study evaluating the effects of a SMI targeting psychosocial issues in patients with pituitary disease and their partners demonstrated promising positive results. Future research should focus on the refinement and implementation of this SMI into clinical practice.
Authors: Cornelie D Andela; Daniel J Lobatto; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz Journal: Pituitary Date: 2018-04 Impact factor: 4.107
Authors: Amir H Zamanipoor Najafabadi; Johannes P M van de Mortel; Daniel J Lobatto; Dieta R Brandsma; Wilco C Peul; Nienke Biermasz; Martin J B Taphoorn; Linda Dirven; Wouter R van Furth Journal: Neurooncol Pract Date: 2019-11-02
Authors: Daniel J Lobatto; Wilbert B van den Hout; Amir H Zamanipoor Najafabadi; Anath N V Steffens; Cornelie D Andela; Alberto M Pereira; Wilco C Peul; Wouter R van Furth; Nienke R Biermasz; Thea P M Vliet Vlieland Journal: Endocrine Date: 2019-03-22 Impact factor: 3.633
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Cornelie D Andela; Thea P M Vliet Vlieland; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz Journal: Endocrine Date: 2020-06-19 Impact factor: 3.633
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Wilbert B van den Hout; Cornelie D Andela; Ingrid M Zandbergen; Alberto M Pereira; Wouter R van Furth; Thea P M Vliet Vlieland; Nienke R Biermasz Journal: Pituitary Date: 2020-10-06 Impact factor: 4.107